statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma

Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma Intensity Therapeutics, Inc. Announces First...

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors PR...

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in...

Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update PR...

Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024

Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024 Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024...

Portage Biotech completes monetization of  Intensity Therapeutics shares

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

Company generated approximately $2.8M of non-dilutive funding to extend cash runwayWESTPORT, Conn., March 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage...

Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024

Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024 Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024 PR Newswire...

Intensity Therapeutics says cash sufficient to fund operations through 1Q25

Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update PR Newswire...

Intensity Therapeutics, Inc. operates as biotechnology company which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Shelton, CT.

Volume	9,802.00
52-Wk High	$11.44
52-Wk Low	$2.01

INTS INTENSITY THERAPEUTICS, INC.

About

Feed

News

Earnings

Fundamentals